高危前列腺癌患者体内分离循环肿瘤细胞的多重基因表达谱分析
该研究首次对高危前列腺癌患者体内分离的循环肿瘤细胞(CTC)进行多重基因表达谱分析,并与三种基于蛋白的CTC检测方法比较。使用CellCollector从108例高危前列腺癌患者和36名健康志愿者体内分离EpCAM阳性CTC,对其中27例治疗前后样本用高灵敏度多重RT-qPCR检测14个基因。结果显示CTC基因表达高度异质,上皮-间质转化(EMT)标志物治疗前阳性率低(2/27,7.4%),治疗后升高(17/27,63.0%),而上皮标志物治疗后呈下降趋势。
要点
- 体内CTC分离联合下游RNA分析有望成为高通量、特异、超灵敏的多重液体活检分子诊断方法。
- 高危前列腺癌患者CTC基因表达高度异质,至少1个标志物在70.5%(74/105)患者中检出。
- EMT标志物阳性率治疗前7.4%(2/27),治疗后升至63.0%(17/27)。
核心结论
- 体内CTC分离联合下游RNA分析作为高通量、特异、超灵敏的多重液体活检分子诊断方法具有高度前景。
研究设计与样本
- 使用CellCollector从108例高危前列腺癌患者和36名健康志愿者体内分离EpCAM阳性CTC。
- 对27例患者治疗前后样本,开发高灵敏度多重RT-qPCR检测14个基因(包括上皮、干细胞和EMT标志物)。
- 与CellSearch、PSA-EPISPOT和CellCollector体内捕获CTC的免疫荧光三种蛋白检测方法在同一次采血中比较。
主要发现
- CTC基因表达高度异质:至少1个标志物在74/105(70.5%)患者中检出,2个标志物在45/105(40.9%),3个标志物在16/105(15.2%)。
- 上皮标志物在31/105(29.5%)患者中检出,EMT标志物在46/105(43.8%),干细胞标志物在15/105(14.3%)。
- EMT标志物阳性率治疗前为2/27(7.4%),治疗后为17/27(63.0%);上皮标志物治疗前为13/27(48.1%),治疗后为2/27(7.4%)。
- 至少2个标志物表达率为40.9%,而CellSearch为19.6%,EPISPOT为38.1%,CellCollector免疫荧光染色为43.8%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molecular characterization of circulating tumor cells (CTCs) is important for selecting patients for targeted treatments. We present, for the first time, results on gene expression profiling of CTCs isolated in vivo from high-risk prostate cancer (PCa) patients compared with CTC detected by 3 protein-based assays-CellSearch®, PSA-EPISPOT, and immunofluorescence of CellCollector® in vivo-captured CTCs-using the same blood draw. METHODS: EpCAM-positive CTCs were isolated in vivo using the CellCollector from 108 high-risk PCa patients and 36 healthy volunteers. For 27 patients, samples were available before and after treatment. We developed highly sensitive multiplex RT-qPCR assays for 14 genes (KRT19, EpCAM, CDH1, HMBS, PSCA, ALDH1A1, PROM1, HPRT1, TWIST1, VIM, CDH2, B2M, PLS3, and PSA), including epithelial markers, stem cell markers, and epithelial-to-mesenchymal-transition (EMT) markers. RESULTS: We observed high heterogeneity in gene expression in the captured CTCs for each patient. At least 1 marker was detected in 74 of 105 patients (70.5%), 2 markers in 45 of 105 (40.9%), and 3 markers in 16 of 105 (15.2%). Epithelial markers were detected in 31 of 105 (29.5%) patients, EMT markers in 46 of 105 (43.8%), and stem cell markers in 15 of 105 (14.3%) patients. EMT-marker positivity was very low before therapy (2 of 27, 7.4%), but it increased after therapy (17 of 27, 63.0%), whereas epithelial markers tended to decrease after therapy (2 of 27, 7.4%) compared with before therapy (13 of 27, 48.1%). At least 2 markers were expressed in 40.9% of patients, whereas the positivity was 19.6% for CellSearch, 38.1% for EPISPOT, and 43.8% for CellCollector-based IF-staining. CONCLUSIONS: The combination of in vivo CTC isolation with downstream RNA analysis is highly promising as a high-throughput, specific, and ultrasensitive approach for multiplex liquid biopsy-based molecular diagnostics.
引用
- Markou A, Lazaridou M, Paraskevopoulos P, et al. Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients. Clin Chem. 2017. PMID: 29122836. doi:10.1373/clinchem.2017.275503
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。